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Abstract
Background: It is estimated that almost a half of all of people living in developing countries today are infected with
roundworms, hookworms, or whipworms or combinations of these types of intestinal nematode worms. They can all be
treated using safe, effective, and inexpensive single-dose generic drugs costing as little as USD 0.03 per person treated
when bought in bulk. The disease caused by intestinal nematodes is strongly related to the number of worms in the gut,
and it is typical to find that worms tend to be aggregated or clumped in their distribution so that ,20% of people may
harbour .80% of all worms. This clumping of worms is greatest when the prevalence is low. When the prevalence rises
above 50%, the mean worm burden increases exponentially, worms are less clumped, and more people are likely to have
moderate to heavy infections and may be diseased. Children are most at risk. For these reasons, the World Health
Organization (WHO) currently recommends mass treatment of children $1 year old without prior diagnosis when the
prevalence is $20% and treatment twice a year when the prevalence is $50%.
Methods and Findings: The risk of moderate to heavy infections with intestinal nematodes was estimated by applying the
negative binomial probability distribution, then the drug cost of treating diseased individuals was calculated based on
different threshold numbers of worms. Based on this cost analysis, a new three-tier treatment regime is proposed: if the
combined prevalence is .40%, treat all children once a year; .60% treat twice a year; and .80% treat three times a year.
Using average data on drug and delivery costs of USD 0.15 to treat a school-age child and USD 0.25 to treat a pre-school
child (with provisos) the cost of treating children aged 2–14 years was calculated for 105 low- and low-middle-income
countries and for constituent regions of India and China based on estimates of the combined prevalence of intestinal
nematode worms therein. The annual cost of the three-tier threshold was estimated to be USD 224 million compared with
USD 276 million when the current WHO recommendations for mass treatment were applied.
Conclusion: The three-tier treatment thresholds were less expensive and more effective as they allocated a greater
proportion of expenditures to treating infected individuals when compared with the WHO thresholds (73% compared with
61%) and treated a larger proportion of individuals with moderate to heavy worm burdens, arbitrarily defined as more than
10 worms per person (31% compared with 21%).
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Introduction
In 2008 the Copenhagen Consensus ranked five nutritional
interventions among the top ten of more than 40 proposals to
answer the question: what would be the best ways of advancing
human welfare globally? [1] Deworming and other nutrition
programmes in school were ranked as the sixth best intervention
overall when considering their potential benefit to cost ratio,
anticipated feasibility and sustainability [1]. As drugs to treat
worms are safe and inexpensive, it is feasible to give periodic mass
treatment without the prior diagnosis of individual infections.
However the cost, benefits and sustainability of mass treatment
depend on the prevalence of infection used to decide whether and
how often to give treatment, and on the proportion of infected
individuals who have disease.
This paper has three sections. First, we introduce some of the
key factors that affect how the disease caused by the three main
types of intestinal nematode worms can be controlled. Second, we
estimate the costs of treating people by mass chemotherapy
depending on the proportion infected and on the number of
worms that might cause disease. To do this we use data on the
distribution among human hosts of the large roundworm, Ascaris
www.plosntds.org 1 March 2009 | Volume 3 | Issue 3 | e402lumbricoides. We then propose some new thresholds for giving mass
treatment based on the cost per diseased person treated and
compare them with the current World Health Organization
(WHO) thresholds. We calculate the costs of deworming children
from the ages of 2 to 14 y in the developing world using national
and sub-national estimates of the prevalence of combined
infections with any species of intestinal nematode worm. We
conclude by discussing the implications of our analysis.
Intestinal worms number among the most common infections of
people in the developing world today. It has been estimated that
1.22 billion people in low, lower-middle and upper-middle income
economies, or 26% of their population, are infected with Ascaris
lumbricoides, 0.80 billion (17%) with Trichuris trichiura and 0.74
billion (15%) with either or both of the two main species of
hookworm, Ancylostoma duodenale or Necator americanus [2]. (These
estimates exclude the former countries in the Commonwealth of
Independent States for which prevalence data are not available).
From these prevalences it has been estimated that about 48% of
the population of these countries, or some 2.3 billion people, are
likely to be infected with at least one of these species of intestinal
nematode worms [3] (which assumes independence between
species in the probability of infection, an assumption that is
discussed further in the next section). The usual method to
diagnose infections is to see the characteristic eggs of worms in
faeces [4]. But the presence of eggs is a poor indicator of the risk of
disease and of the impact of treatment because only two worms – a
male and a female – are necessary to produce eggs, and two worms
are very unlikely to cause disease. The risk of being diseased
depends principally on the species and number of worms in the
gut, as well as on the site in the gut in which the worms live, the
mechanism by which worms feed, the duration of infection, the
inflammatory and immune responses to infection, and the size, age
and current health of the infected person [3].
In simple numerical terms disease due to each species of
intestinal nematode worms tends to be associated with moderate to
heavy worm burdens, but there is no accepted number of worms
that defines moderate to heavy infections for each species. Worms
do not multiply within their host and each worm is the result of
exposure to a fertilised and mature egg or larva. It is typical to find
that worms are not randomly or evenly distributed between hosts
and that more than 80% of all worms are present in less than 20%
of all hosts [5]. This aggregated or clumped distribution of worms
in a small proportion of hosts is best described empirically by the
negative binomial probability distribution [5]. Observations of the
numbers of A.lumbricoides, the worm most commonly studied, show
that the degree of aggregation of worms among human hosts is
greatest when the mean worm burden is low [6]. As the force of
infection increases and the prevalence rises, the mean worm
burden increases in a strikingly non-linear way (Figure 1) such that
the degree of aggregation decreases and a larger proportion of
individuals have moderate to heavy infections [7,8].
Because worms are most aggregated when prevalence is low, at
a prevalence of ,50% only a small proportion of infected people
will have disease due to a moderate to heavy worm burden and
will therefore benefit from treatment. When the prevalence of
infection is .50%, the cost-effectiveness of treatment rises because
a larger proportion of the population have moderate to heavy
worm burdens and are likely to be diseased.
The final important epidemiological characteristic of intestinal
nematode worms is that surveys typically show that school-age
children tend to harbour the heaviest infections with Ascaris
lumbricoides and Trichuris trichiura [8,9] and are the group in the
population most likely to suffer from disease. As it is relatively easy
to deliver treatments to children through the educational system, if
they are enrolled, this can serve to minimise delivery costs [10] as
well as having consequences for both health and education of
children, two major benefits of treatment [11].
Mass treatment of children for worms is potentially cost-
effective for number of reasons. First, when the prevalence of
infection is greater than 50% the purpose of diagnosis becomes
more to identify uninfected individuals to exclude from treatment
than to identify those to treat. Second, the cost of the drugs to treat
worms is measured in US cents while the cost of collecting and
examining stool samples under a microscope to diagnose worms is
measured in US dollars [12]. Third, the drugs to treat worms are
very safe, meaning that there is no known harm for an uninfected
person to be treated; they are effective to different degrees against
all species of intestinal nematode [13]; and they can be given as a
single, oral dose, which eliminates issues of compliance with
treatment [14,15]. Finally, as Figure 1 shows, the mean worm
burden increases exponentially at prevalences above 50% and so,
therefore, does the risk of disease [7].
As reinfection with intestinal worms can occur immediately
after treatment, the aim of deworming is first, to reduce the
number of worms substantially and eliminate disease, and then to
repeat treatment often enough to prevent moderate to heavy loads
from being re-accumulated [16].
In 1996 a WHO informal consultation endorsed a recommen-
dation that a combined prevalence of any species of intestinal
nematode worms of $50% was sufficient to warrant mass
treatment of school-age children [17]. The WHO then developed
a complicated strategy to decide how often to give mass treatment
based on three categories of prevalence and the proportion of
moderate to heavy infections based on arbitrary egg counts for
each separate species [16]. This required an estimate of the
concentration of eggs in faeces, which is not easy to do in a small
rural hospital laboratory unless the necessary materials are
supplied. The fecundity of worms, which largely governs the
concentration of eggs in faeces, has also been shown to be highly
variable between worms in different countries, for A.lumbricoides at
least [18]. The practicability and the biological basis of this
recommendation were therefore weak.
In 2006 another WHO informal consultation endorsed a
reduction in the threshold for mass treatment in a simplified
Author Summary
Almost one in every two people in the developing world is
infected with one or more types of intestinal nematode
worms. When fewer than 50% of people are infected, most
carry only a few worms; but when more than 50% are
infected, the number carrying moderate to heavy numbers
increases markedly, as does the risk of disease. The WHO
recommends annual mass deworming of children when
20% or more are infected and twice a year if 50% or more
are infected. We estimated the cost of this to treat children
with 10+ worms, an arbitrary moderate to heavy infection.
We concluded that it is not cost-effective to mass treat
children when fewer than 40% are infected because the
majority are uninfected and few are likely be diseased. We
propose annual treatment when 40% or more children are
infected, twice a year at 60%, and three times a year at
80% or more. This would cost USD 224 million annually to
treat all children aged 2–14 years in 107 developing
countries compared with USD 276 million using current
WHO guidelines. The new three-tier guidelines also treat a
larger proportion of infected children and treat children
with moderate to heavy worm burdens more often.
Cost-Effectiveness of Mass Treatment Thresholds
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of children are infected with intestinal nematode worms, then mass
treatment is recommended for all school-age children once a year;
if $50% of children are infected, then mass treatment is
recommended twice a year [19]. Provision was also made for
treatment three times a year if the prevalence of infection was
$50% and if resources were available, but no different or higher
threshold was specified [19]. The complicated strategy based on
separate egg counts for different species was effectively superseded.
Mass deworming was promoted globally in 2001 when the 54
th
World Health Assembly adopted a resolution to deworm at least
75% of all school-age children at least once a year in countries
where intestinal worms were endemic [20], which is most of the
developing world [2]. The most recent data available for 64 (49%)
of the 130 countries in which worms are endemic indicated that
coverage of schoolchildren was 22% [21], suggesting that the
numbers presented in the most recent global estimates of the
prevalence of infection [2] may not have changed significantly.
Data for preschool children from 51 countries (39%) indicate that
coverage has reached 55% [21].
Methods
The cost of giving mass treatment with an anthelmintic drug was
estimated inthree ways:asthe costperperson treated,as the costper
infected person treated, and as the cost per moderately-to-heavily
infected person treated. The calculations were based on a drug cost
of USD 0.03 per person, a typical price for a generic anthelmintic
when bought in moderate quantities in a developing country.
The proportion of people who are infected is usually estimated
by a survey to determine which people in a sample of the
population have the eggs of worms in their faeces. The proportion
of people who are moderately or heavily infected depends on two
factors: how worms are distributed between individuals within a
population and the threshold number of worms used to classify a
worm load as a moderate infection.
The distribution of worms between hosts can usually be
described empirically by the negative binomial probability
distribution in which the prevalence p=12(1+M/k)
2k where M
is the mean worm burden and k is a clumping parameter. Values
of k are typically ,1.0 for intestinal nematode worms [5] and
reflect the observation that most worms tend to be aggregated in a
small proportion of all hosts. The negative binomial probability
distribution was applied to estimate the proportion of individuals
with more than any given threshold number of worms, as follows.
The observed linear relationship between the mean worm
burden and the clumping parameter for A.lumbricoides, in which
k=0.334+0.0172 M [6], was used to estimate values of k for values
of M in steps of roughly M/2, starting at M=30, the highest mean
worm burden ever reported [22]. These values of M and k were
then used to estimate the proportion infected by applying the
equation for the negative binomial distribution. Values of M were
adjusted, which also altered k, to give proportions infected ranging
from 20% to 95% in steps of 10% to 80% and then steps of 5% to
95%.
In the next stage the values of k and M for each value of
prevalence between 20% and 95% were entered into the negative
binomial function (pnbinom) of R statistical software version 2.7.2
[23] to estimate the proportion of people in any population who
have more than 5, 10, 15 or 20 worms, arbitrary thresholds which
could be applied to classify a worm burden as moderate or heavier.
The final values of p, M and k used to estimate the proportions of
moderately to heavily infected individuals are shown in Table 1.
Although this analysis is based on data for a single species of
worm, Ascaris lumbricoides, it may apply to other species of intestinal
worms because the distribution of disease for any species is driven
largely by the extent to which worms are aggregated in a few hosts,
so the clumping parameter k is of great importance. As values of k
range from 0.03–0.6 for hookworms and from 0.2–0.4 for
whipworms [5], they indicate a greater degree of aggregation of
these species than for roundworms, values for which range from
0.3–0.9 [5]. Similarly the coefficients in the equation linking k and
the worm burden M in Table 1 have been estimated for
roundworm, but are not known so well for the other species.
Hence the numerical values used in this analysis are not
necessarily a perfect guide to cases of infection with whipworm
Figure 1. The relationship between the prevalence of infection with an intestinal nematode worm, in this case Ascaris lumbricoides,
and the mean worm burden estimated by applying the negative binomial distribution using a clumping parameter (k) that varies
linearly with the mean worm burden (see ref. [6]).
doi:10.1371/journal.pntd.0000402.g001
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of intestinal worm. However the main point, that worms are most
highly aggregated at low prevalences of infection, is likely to hold
true for all species.
As there are no existing classifications of the numbers of worms
of any species that cause disease they can only be guessed at based
on a knowledge of the size of worms or the estimated effects of
individual worms. For example, assuming an equal sex ratio, 5
A.lumbricoides weigh about 12 g, 10 worms weigh about 25 g, 15
worms weigh 35 g and 20 worms weigh about 45 g, which is about
0.3% of the body weight of an underweight 6-year old child
weighing 15 kg [24]. The energy requirements of a worm burden
such as this are thought to be relatively small in comparison with
the host, but worms may have more important effects on absorption
and appetite [3]. For the hookworm species A.duodenale, 5 worms are
estimated to cause a blood loss of 1 ml/day, 10 worms 2 ml/day, 15
worms 3 ml/day and 20 worms 4 ml/day; the same figures for the
other hookworm species, N.americanus, are 0.2, 0.4, 0.6 and 0.8 ml/
day of blood a day, as the two species differ in the volume of blood
loss that they cause [25]. But as both species now occur together
widely throughout the world, mixed infections are very likely [26].
The loss of blood caused by the same number of whipworms is
estimated to be 0.02, 0.05, 0.07 and 0.1 ml/day of blood [27]
although the inflammatory response to the head of the worms
embedded in tissues may be more important.
For the purposes of calculating the number of moderately to
heavily infected individuals and to estimate the costs of treating
them on the assumption that they are diseased, thresholds burdens
of $5, $10, $15 and $20 worms were used to estimate the cost
of treating each diseased person. This analysis is presented in
Table 1 and shows that when an arbitrary threshold of 10 worms is
used to define a moderate infection, a cost-effective threshold for
giving mass treatment of less than USD 1 per diseased person
treated lies between a prevalence of 40% and 50%. We therefore
propose the following new thresholds for mass treatment, which
we call the three-tier treatment thresholds:
N when the prevalence is 40% to ,60%, mass treat once a year;
N when the prevalence is 60% to ,80%, mass treat twice a year;
N when the prevalence is 80% to 100%, mass treat three times a
year.
These thresholds are both simple and evenly incremental and
they apply treatment more often in circumstances in which the risk
of moderate to heavy infections is highest.
When the prevalence is ,40% we propose that only
underweight, wasted or anaemic children should be treated as a
matter of course or that internationally recommended guidelines
should be followed, such as those for the Integrated Management
of Childhood Illness.
As the estimates of cost presented in Table 1 do not include the cost
of delivering treatments, the second stage of the analysis was to
estimate and compare the cost of delivering an anthelmintic drug
costing USD 0.03 per dose to all children in the developing world by
applying either the WHO guidelines or the new three-tier guidelines.
To do this estimates were made of the prevalence of infection with
any type of intestinal nematode worms in 107 developing countries,
of the numbers of children to be given mass treatment in the same
developing countries, and of the costs of delivering treatments to all
pre-school and school-age children, as follows.
As most surveys report the prevalence of each worm species
separately, rather than as a combined prevalence of intestinal
nematode worms, the combined prevalence in each of 107
developing countries was estimated using data from ref. [2] based
on the assumption that the probability of infection with one species
was independent of infection with any other. For example, if the
prevalence of infection with A.lumbricoides was 60% and the
prevalence of T.trichiura was 40%, then the prevalence of joint
infections was estimated to be 0.660.4=0.24. Thus the propor-
tion infected with either or both species was estimated to be: (0.6–
0.24)+(0.4–0.24)+0.24=0.76. A preliminary analysis of data from
38 surveys in 16 countries which reported the combined
prevalence of any species of intestinal nematode as well as the
Table 1. Estimates of the costs of treating infections with Ascaris lumbricoides using a drug costing USD 0.03 per dose calculated
in three ways: per person treated, per infected person treated, and per diseased person treated defined using four different
thresholds of worm burden.




























0.95 30.0 0.850 0.8158 0.6860 0.5817 0.4956 0.03 0.03 0.04 0.04 0.05 0.06
0.90 20.0 0.678 0.6988 0.5430 0.4322 0.3483 0.03 0.04 0.04 0.06 0.07 0.09
0.85 14.5 0.583 0.6032 0.4377 0.3295 0.2526 0.03 0.04 0.05 0.07 0.09 0.12
0.80 11.0 0.523 0.5241 0.3563 0.2539 0.1852 0.03 0.04 0.06 0.08 0.12 0.16
0.70 6.4 0.442 0.3783 0.2188 0.1354 0.0865 0.03 0.04 0.08 0.14 0.22 0.35
0.60 3.6 0.396 0.2530 0.1159 0.0580 0.0302 0.03 0.05 0.12 0.26 0.52 0.99
0.50 2.0 0.368 0.1456 0.0460 0.0162 0.0060 0.03 0.06 0.21 0.65 1.85 5.01
0.40 1.2 0.354 0.0766 0.0149 0.0033 0.0008 0.03 0.07 0.39 2.01 9.09 38.88
0.30 0.6 0.345 0.0222 0.0016 0.0001 0.0000 0.03 0.10 1.35 18.80 230.81 2,658.33
0.20 0.3 0.339 0.0041 0.0001 0.0000 0.0000 0.03 0.15 7.35 485.68 27,335.62 1,435,480.19
The method used to calculate the parameters is described in the text. Some values for the proportion infected were ,0.0001. Adapted from ref [48].
ak=a+bM in which a=0.334 and b=0.0172 [7].
doi:10.1371/journal.pntd.0000402.t001
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the observed prevalence and the calculated combined prevalence
using this method of 0.99 (P,0.0001) (data not reported).
Using these survey data the combined prevalence of all three
main types of intestinal nematode worms was estimated for most
developing countries. Because China and India contain a large
proportion of the world’s children, sub-national data on
prevalence taken from the 2
nd national survey were used for
China’s provinces, autonomous regions or municipalities [28], and
data from a previous analysis were used for India’s states or union
territories [2]. The data were then mapped.
The number of children aged 2–14 years in the same
developing countries was estimated for each county and for the
separate provinces of China and states of India using United
Nations population data [29] and data from the censuses of China
[30] and India [31] by applying World Health Organization life
tables [32]. The numbers used in these calculations are given in
Tables S1 and S2.
Estimates of the cost of delivering a single dose drug to treat
intestinal nematode worms were derived from published reports,
summarised in Table 2. A cost per round of treatment of USD 0.25
for each pre-school child and USD 0.15 per school-age child was
used in the analysis. These costs assume that a generic drug costing
USD 0.03 is applied and that deworming is combined with another
intervention for preschool children or is given in schools with
another treatment such as praziquantel, thus apportioning the
distribution and delivery costs with at least one other intervention.
The combined prevalence of any intestinal nematode worm was
then used to classify countries into those requiring none, one or
two annual treatments in the first year based on the current WHO
thresholds, or requiring none, one, two or three annual treatments
in the first year using the three-tier treatment thresholds. The total
cost was calculated as well as the proportion spent on treating
infected people only and the proportion spent on treating people
with 10 or more worms.
Results
Table 1 shows the values of p, M and k used to estimate the
proportions infected with between 5 or more to 20 or more Ascaris
lumbricoides with the cost per person, per infected person and per
diseased person, depending on the threshold number of worms
used to define disease.
When the prevalence of infection approaches 100%, as it can in
places where transmission is very intense, then the cost per infected
person treated approaches the cost per person treated. However
when the prevalence is ,100% some uninfected people will be
treated unnecessarily, so that when the prevalence is as low as
20%, the minimum prevalence at which the WHO recommend
mass treatment [19], the cost of drugs per infected person treated
is 5 times the cost per person treated (Table 1).
Table 1 also shows that when the prevalence is 20% only 0.004%
of individuals may have $5 worms, a relatively low threshold at
which disease might occur. When mass treatment is given at this
threshold the drugs alone would cost USD 7.35 per person treated
with5 ormore worms. For a threshold of10 ormore worms the cost
is USD 485 per diseased person treated and when the threshold is
increased to 15 or 20 worms, the cost is two orders of magnitude
greater for each increase of 5 worms (Table 1).
Figure 2 shows a map of the combined prevalence of infection
with all three main types of intestinal nematode worms in 107
developing countries. Table 3 shows how these countries, the
provinces of China and the states and territories of India are
classified into six groups requiring none, one, two or three annual
treatments in the first year using the current WHO thresholds and
the new three-tier treatment thresholds.
Table 4 shows the total costs of applying treatments based on
the classification of countries by group in Table 3. The new three-
tier guidelines cost almost 20% less than the current WHO
guidelines, at USD 224 m compared with USD 276 m. This is
because although the new guidelines recommend fewer treatments
when the prevalence is low, this is partially offset by more frequent
treatment at higher prevalences, thus focussing resources in places
where moderate to heavy infections are most likely [19].
Because of the different thresholds at which a single annual
treatment is given, the new three-tier thresholds spent 73% of
expenditure on treating infected individuals in the first year
compared with 61% for the WHO guidelines (Table 4). This
means that 27% and 39% of costs respectively were used to treat
uninfected individuals, an inevitable consequence of giving mass
treatment.
The new guideline also led to greater spending on treating
moderately to heavily infected individuals. The proportion of
expenditures on treating individuals with burdens of 10 or more
worms was 31% for the three-tier guidelines compared with 21%
for the WHO guidelines (Table 4).
Table 2. Estimates of the cost of delivering single dose treatments with albendazole (ALB) or praziquantel (PZQ) to treat pre-
school and school children for infections with intestinal nematode worms or Schistosoma spp respectively.
Country Group Treatment Delivery cost per child per dose Reference
Ghana Schoolchildren Albendazole, Praziquantel USD 0.07 (ALB), USD 1.19 (PZQ)
Including costs of volunteers time
[10]
Tanzania Schoolchildren Albendazole, Praziquantel USD 0.04 (ALB), USD 0.30 (PZQ)
Including costs of volunteers time
[10]
Uganda Schoolchildren Albendazole, Praziquantel (if schisto .30%),
once/year
USD 0.54 (USD 0.32 excluding drug
cost for PZQ)
[38]
Tanzania Schoolchildren Albendazole, Praziquantel (if schisto .50%), once/year USD 0.23/round ALB, USD 0.79 PZQ [49]
Ethiopia Preschool children Albendazole, Vitamin A USD 0.57 incl also vitamin A
(vitamin A & worm supply costs similar)
[50]
Note. All programs combined the distribution of drugs to treat intestinal nematodes with another intervention, either praziquantel for schoolchildren or vitamin A for
preschoolers. The costs in stand-alone programmes would be higher, as distribution costs would not be shared with another programme. Although costs are only
available for countries in Africa, these are considered to be a reasonable guide to costs in South, Southeast and East Asia. Costs in Latin America and the Caribbean are
likely to be higher due to higher salary costs.
doi:10.1371/journal.pntd.0000402.t002
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continuing costs will depend on the prevalence of infection and
whether it is reduced to a lower threshold band. If so, the
frequency of subsequent treatments can be reduced. To assess a
change in prevalence will require data from small surveys before
and after treatment, though the interval could be as infrequent as
every two years, depending on local resources and capacity.
Discussion
The analysis presented here indicates that a prevalence of
infection with any species of intestinal nematode worm of 40% or
more provides a cost-effective threshold at which to give mass
treatment once a year. Because the proportion of moderate to
heavy infections increases non-linearly with an increasing
prevalence (Figure 1), higher thresholds of 60% and 80% provide
a simple but epidemiologically sound and cost-effective basis on
which to treat twice or three times a year, at least in the first 1–
2 years of a programme. While models of reinfection indicate that
it may be more important to achieve higher population coverage
than more frequent treatment, [33] it is easier and less costly to
achieve high coverage of children than adults. Giving treatments
three times a year in places with a high initial prevalence will bring
down mean worm burdens more quickly than treating only twice a
year, while missing one of three treatments will achieve better
annual coverage of any given individual than if one of only two
treatments is missed, as the WHO recommend when the initial
prevalence is greater than 50%. As children with moderate to
heavy worm burdens tend to become moderately to heavily
reinfected after treatment because of unknown factors that
contribute to a predisposition to heavy infections [34–36] it may
be better to specify three rather than two annual treatments in
order to sustain low worm burdens in the face of rapid reinfection
[37]. It has also been shown that over several cycles of treatment
and reinfection with A. lumbricoides, at least two thirds of all
individuals treated may become moderately heavily reinfected at
least once [37] so that, over time, a large proportion will benefit
from repeated treatment.
This analysis shows that when the costs of deworming drugs are
calculated per individual treated it ignores that fact that not
everyone is infected and underestimates the cost per infected
person treated. Likewise, when the costs of deworming are given
per infected individual treated it ignores the fact that not everyone
has a significant worm burden and underestimates the cost per
moderately or severely infected person treated.
The estimates of the cost of deworming drugs shown in Table 1
attempt to take into account the distribution of disease caused by
intestinal nematode worms, which is affected mainly by the worm
burden. But this depends on the epidemiological parameters used
in the negative binomial distribution and the threshold burden at
which disease is classified, which is arbitrary. But if the same
biological factors that cause the aggregation of A.lumbricoides also
apply to T.trichiura, A. duodenale and N.americanus, then it could be
argued that if the disease they cause is additive rather than
Figure 2. A map of the prevalence of infection with any species of intestinal nematode worms derived from data presented in ref [2]
on the national prevalences of combined infections with Ascaris lumbricoides, Trichuris trichiura and the two hookworm species
Ancylostoma duodenale and Necator americanus. The method of calculation is described in the text.
doi:10.1371/journal.pntd.0000402.g002
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could apply to the combined number of worms of any of these
species to define disease. It would be worthwhile undertaking
further research on the worm burdens of mixed infections, since
these are the basis for treatment thresholds.
The analysis presented in Table 1 suggests that the cost of
treating diseased people becomes uneconomically high when the
prevalence is less than 40%. Cost-effectiveness data do not support
the preventive chemotherapy approach of treating once per year
for prevalence rates as low as 20%, unless an appropriate
longitudinal model of reinfection and disease can be developed
that would justify treatment.
The costs of delivering treatments will depend on local
circumstances but tend to be an order of magnitude greater than
the cost of the drugs. Delivery costs are typically around four times
the cost of the drugs for schoolchildren and six times the cost for
preschoolers (Table 2). Delivery costs may also vary with
population density [38], probably because fixed delivery costs
are divided by a larger denominator. The implication is that the
marginal cost of increasing coverage is likely to increase as
coverage also increases. Whether the marginal benefit also
increases as coverage of treatment reaches remote populations
will depend on whether worm burdens are higher in more remote
areas, perhaps because of lack of access to sanitation for example,
or lower, perhaps because of lower population density and lower
transmission.
The coverage of school-age children will depend largely on
enrolment rates which are improving as a result of global efforts to
achieve one of the Millennium Development Goals, but will
probably miss many non-enrolled children. But there is no reason
why coverage of children who are enrolled and attending school
should not approach 100%, especially if children who are absent
from school are treated later. In any case, there are externalities in
terms of treatment and its effects on reducing transmission that will
also benefit those children who miss being treated. Mass treatment
has been shown to lead to a reduced prevalence of infection
among untreated people [39,40].
As programmes to control both intestinal nematode worms and
lymphatic filariasis using albendazole given with ivermectin or
DEC have been implemented recently in parts of some countries,
Table 3. Classification of countries (see Table S1) and regions of India and China (see Table S2) by prevalence of infection and
annual treatment frequency (x0, x1, x2 or x3 times) based on current WHO guidelines [19] and the new three-tier guidelines
proposed here.
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Prevalence: ,20% Prevalence: 20–39% Prevalence: 40–49% Prevalence: 50–59% Prevalence: 60–79% Prevalence: $80%
WHO: x0 WHO: x1 WHO: x1 WHO: x2 WHO: x2 WHO: x2 (flexible)
Three-tier: x0 Three-tier: x0 Three-tier: x1 Three-tier: x1 Three tier: x2 Three tier: x3
Algeria Argentina Botswana Burundi Cambodia Angola
Benin Bahamas Brazil Central African Rep. El Salvador Bangladesh
China (20 provinces) Barbados China (3 provinces) China (1 province) Ethiopia Cameroon
Dominican Rep. Bolivia Colombia Guinea Haiti Congo
Egypt Chad Ecuador India (4 states) Honduras Congo DR
Eritrea Chile Ghana Jamaica India (2 states) Cote d’Ivoire
India (15 states) China (7 provinces) India (5 states) Kenya Indonesia Equatorial Guinea
Iran Costa Rica Malawi Namibia Laos Fiji
Iraq Grenada Mozambique Panama Madagascar Gabon
Jordan Guinea-Bissau Senegal Peru Malaysia Guatemala
Lebanon Guyana Somalia Maldives Liberia
Libya India (9 states) Sri Lanka Myanmar Micronesia
Mauritania Mali Suriname Nepal Philippines
Mongolia Mauritius Tanzania Nigeria Rwanda
Morocco Mexico Thailand Papua New Guinea Samoa
Oman Nicaragua Uganda Paraguay Sao Tome and Principe
Pakistan Niger Venezuela Sierra Leone Solomon Islands
Puerto Rico St. Lucia South Africa Tonga
Saudi Arabia St. Vincent The Gambia Vanuatu
Syria Sudan Togo
Trinidad & Tobago Yemen Vietnam
Tunisia Zambia
Uruguay Zimbabwe
Columns 2, 4 and 6 with titles in italics represent differences in approach. Note: 10 developing countries were excluded due to lack of prevalence data (Afghanistan,
Belize, Bhutan, Cape Verde, Comoros, Cuba, Djibouti, Lesotho, North Korea and Swaziland). Another 11 smaller countries did not have population age structure data
available, and were also omitted: (American Samoa, Antigua, Cook Islands, Dominica,Kiribati, Marshall Islands, Nieu, Palau, Seychelles, St. Kitts, Tuvalu). The former
Commonwealth of Independent States countries are also excluded due to lack of revalence data. Source: authors’ calculations. Prevalence data are provided in Table S1
(national data) and Table S2 (subnational data for India and China).
doi:10.1371/journal.pntd.0000402.t003
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been reduced to some degree. This may mean that the aggregate
costs for both sets of guidelines may be overestimated.
In order to improve cost-effectiveness it is recommended that
small surveys of the prevalence of intestinal nematode worms be
undertaken to establish the need for treatment and its frequency
and then repeated every one to two years, depending on resources
and capacity, to monitor prevalence and decide how often
treatment should be given each year. Faecal egg counts should
be estimated as a matter of good practice about 21 days after
treatment to assess both the cure rate and the egg reduction rate in
order to detect drug resistance [17]. However egg counts may not
give a good estimate of the effect of treatment on worm loads if the
fecundity of any remaining worms rises after treatment because of
the partial removal of density dependent constraints on egg
production [41]. Although such surveys increase costs modestly,
they can increase cost-effectiveness by avoiding unwarranted
treatments.
It is also important to state that deworming is a short to medium
term intervention to control disease due to intestinal worms and
that efforts should also be made in schools and communities to
install, maintain and use sanitary latrines [42], to provide clean
water and soap to remove worm eggs from contaminated hand
before eating; and to promote healthy behaviours through health
education [43]. These are the long term measures that will help to
sustain a reduced prevalence of infection by keeping people and
their faeces apart.
The estimated cost of the three-tier approach of over USD
224 million in the first year (USD 276 million using the WHO
guidelines) to treat all children in the countries listed in Table 4
is a large expenditure, but it should decline annually as the
prevalence goes down. However, the potential benefits in terms
of improved child health and education are very large if a
benefit:cost ratio of 6:1 is applied for preschool children [44],
and are even higher for school-age children for whom the
delivery costs are lower. One estimate is 60:1, although this
excludes the cost of hiring additional teachers if participation
rates in education increase [40].
There are current programmes to treat schoolchildren support-
ed by governments and NGOs in sub-Saharan Africa, the Indian
sub-continent and Asia [45]. Some countries, such as Ethiopia,
Bangladesh and Uganda, are giving mass treatment with
albendazole or mebendazole to preschool children at the same
time as they give vitamin A, for example during Child Health
Days [46,47]. Delivery costs may also be reduced if they can be
split with other programmes, such as lymphatic filariasis control,
which provides albendazole in addition to ivermectin or diethyl
carbamazine. There is now a need to collect sub-national data,
probably for regions or provinces in all countries in which worms
are endemic, and to refine these calculations based on local
prevalence data and local cost circumstances. This will provide
accurate local and national estimates of the costs of treating a
group of worms that make a major contribution to the burden of
neglected tropical disease.
Supporting Information
Table S1 Data for each country on the prevalence of infection
with any of the main types of intestinal nematode worm, the
population aged 0–15 years and the proportion aged 2–14 y, used
for the classification of countries in Table 3 and the calculations in
Table 4.
Found at: doi:10.1371/journal.pntd.0000402.s001 (0.12 MB
DOC)
Table S2 Sub-national data for India (left) and China (right) on
the prevalence of infection with any of the main types of intestinal
nematode worm, the total population, and the population aged 2–
14 y, used for the classification of states and territories of India and
provinces, autonomous areas and municipalities of China in
Table 3 and for the calculations in Table 4.
Found at: doi:10.1371/journal.pntd.0000402.s002 (0.10 MB
DOC)
Table 4. Annual costs of treating children aged 2–14 y by countries grouped by prevalence (see Table 3) and depending on the
frequency of treatment given according to current WHO recommended thresholds [19] and the new three-tier thresholds
proposed here.
Country group from Table 3 Prevalence of infection % USD millions USD millions
Three-tier thresholds WHO thresholds
Group 2 20–39 0 54.6
Group 3 40–49 23.7 23.7
Group 4 50–59 22.4 44.8
Group 5 60–79 102.8 102.8
Group 6 80–100 74.8 49.9
Total 223.7 275.8
% spent on initially-infected individuals 72.6% 61.1%
% spent on individuals initially infected with 10+ worms 31.0% 21.4%
Notes. The population estimates are for children aged 0–14 y from ref. [29] converted to age range 2–14 y using the best approximation possible taken from the WHO
Life Tables [32] as follows. The number of person-years lived, nLx was applied to obtain total person-years lived from zero to below the age of 15 y (15L0) and from this
was subtracted the number of person-years lived below the age of 1, one quarter of the person-years lived between 1 and 5, and one fifth of the person-years lived
between 10 and 15, to obtain the proportion of the under-15 population who are at least 2 years old and 14 y or under: i.e. 12L2= 15L02(1L0+0.25*4L1+0.2*5L10). The
underlying data are provided in Table S1. Note that the estimates of percentages spent on initially-infected individuals, and those initially infected with 10+ worms, are
based on static prevalence, and do not take into account declining prevalence with re-treatment. A dynamic model would be desirable.
doi:10.1371/journal.pntd.0000402.t004
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